Argen X SE - ADR opened lower at $896.79, compared with its previous close of $897.85. In the last trading session, the stock traded between $896.20 and $916.05. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Argen X SE - ADR is now worth
$ 298.95
giving a profit of
$ 198.95 (198.95%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 19 Analysts
Buy
94.74%
Hold
5.26%
Sell
0%
Markets Today
Today's Change
+$4.86 (+0.54%)
Day High
$916.05
Day Low
$896.20
Day Open
$896.79
Prev Close
$897.85
Volume
2,21,310
1W Return
3.17%
1M Return
-7.03%
3M Return
2.26%
6M Return
16.33%
1Y Return
9.82%
Fundamentals
Market Cap ($ Mn)
56,768
PE Ratio
38.99
PB Ratio
7.60
PEG Ratio
1.15
ROE
25.18%
ROCE
17.65%
EPS (TTM)
$8.09
Investment Returns
1 Week
3.17%
1 Month
-7.03%
3 Months
2.26%
6 Months
16.33%
9 Months
6.49%
Financials
Quarterly
All values in $ Mn
790.7
Mar 25
948.0
Jun 25
1.1K
Sep 25
1.3K
Dec 25
1.5K
Jun 26
1.7K
Sep 26
Updates
20Oct
RBC Capital lowers argenx price target to $1025, keeps Outperform
RBC Capital analyst Luca Issi lowered the price target to $1025. The previous price target was set at $1100. The Outperform rating on the stock remains unchanged.
10 days ago
19Oct
argenx to present Phase 3 VYVGART Hytrulo data for myositis at ACR
argenx SE to present Phase 3 ALKIVIA study data on VYVGART Hytrulo at ACR Convergence 2026. Study evaluates efgartigimod in immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Clinical improvements observed as early as Week 4 and sustained through 52 weeks. Late-breaking oral presentation scheduled for November 11, 2026, in Orlando, Florida.
11 days ago
14Oct
Wells Fargo maintains Overweight on argenx, raises price target to $1356
Wells Fargo maintains Overweight rating on argenx. Price target raised to $1356 from $1355. Analyst Derek Archila issued the revised estimate.
16 days ago
9Oct
Argenx shares drop 10% as Unity trial halted, investigation launched
Argenx discontinued Phase 3 UNITY study for Sjögren's disease due to futility. ARGX shares fell over 10% ($96.73/share) in pre-market trading on October 8, 2026. SueWallSt launches investigation into potential securities law violations regarding study disclosures. Safety profile remained consistent with established efgartigimod data despite efficacy failure.
21 days ago
18Sep
argenx appoints Brakel and Farooq as non-executive directors
argenx SE held its Extraordinary General Meeting of Shareholders on September 17, 2026. Thomas M. Brakel and Khurem Farooq appointed as non-executive directors. Chairperson Tim Van Hauwermeiren highlighted focus on scientific innovation and Vision 2030.
1mo ago
1Sep
Argenx to present at Wells Fargo and Morgan Stanley healthcare conferences
Argenx management to hold fireside chats at Wells Fargo and Morgan Stanley conferences. Wells Fargo session scheduled for September 8, 2026 in Boston. Morgan Stanley session set for September 14, 2026 in New York. Live webcasts and 30-day replays available on company website.
